From: Factors related to outcome of bloodstream infections due to Candida parapsilosis complex
Characteristics | 30-day outcome | ||
---|---|---|---|
Survival (n = 46) | Death (n = 17) | P valuea | |
Age (years), median (IQR)b | 62 (31–75) | 76 (63–78) | 0.046 |
Male sex, n (%) | 24 (52) | 11 (65) | 0.374 |
Ward | |||
Internal Medicine, n (%) | 21 (46) | 4 (24) | 0.033 |
Surgery, n (%) | 14 (30) | 3 (18) | |
Intensive Care Unit, n (%) | 11 (24) | 10 (59) | |
Comorbidities, n (%) | 40(87) | 17(100) | 0.117 |
Chronic pulmonary diseases, n (%)c | 5(11) | 4 (24) | 0.235 |
Haematological malignancy, n (%) | 1 (2) | 0 (0) | 0.540 |
Cardiovascular diseases, n (%)d | 15 (33) | 12(71) | 0.006 |
Neurological diseases, n (%)e | 9 (20) | 1(6) | 0.263 |
Gastrointestinal diseases, n (%)f | 16 (35) | 5 (29) | 0.688 |
Diabetes mellitus, n (%) | 4 (9) | 4 (24) | 0.195 |
Solid tumors, n (%) | 9 (20) | 6 (35) | 0.193 |
Chronic renal failure, n (%) | 5 (11) | 2 (12) | 1.000 |
Previous surgery (<30 days), n (%) | 23(50) | 9(53) | 0.835 |
Gastrointestinal surgery, n (%) | 5(11) | 3(18) | 0.671 |
Cardiovascular surgery, n (%) | 7(15) | 6(35) | 0.080 |
Other surgery, n (%)g | 11(24) | 1 (6) | 0.154 |
Central venous catheter, n (%) | 41(89) | 15 (88) | 0.920 |
BSI CVC-related, n (%) | 25 (61) | 11 (73) | 0.460 |
Early central venous catheter removal, n (%)h | 41 (100) | 11 (73) | <0.0001 |
Other devices, n (%)i | 40 (87) | 17(100) | 0.178 |
Previous invasive procedures (<72 h), n (%)j | 9 (20) | 7 (41) | 0.080 |
Parenteral nutrition, n (%) | 29 (63) | 14 (82) | 0.143 |
Immunosuppressive therapy, n (%)k | 13(28) | 5(29) | 0.920 |
Neutropenia, n (%) | 3 (7) | 1 (6) | 1.000 |
Septic shock, n (%) | 1(2) | 1(6) | 0.470 |
Prior antibiotic therapy, n (%) | 42 (91) | 16 (94) | 0.713 |
Previous antifungal therapy, n (%) | 4 (9) | 1 (6) | 0.713 |
Concomitant bacteriemia, n (%) | 12(26) | 3(18) | 0.487 |
Other coinfections, n (%)l | 28 (61) | 11(65) | 0.780 |
Appropriate antifungal therapym | 30 (65) | 8 (47) | 0.190 |
Primary azole therapy | 32 (70) | 9 (53) | 0.219 |
Primary echinocandin therapy | 5 (11) | 2 (12) | 1.000 |
Primary polyene therapy | 1 (2) | 0 (0) | 1.000 |
None | 8 (17) | 6 (35) | 0.129 |